Cardioneuroablation for the Treatment of Vasovagal Syncope: Current Status and Impact on Quality of Life.
Curr Cardiol Rep
; 25(12): 1839-1849, 2023 12.
Article
en En
| MEDLINE
| ID: mdl-37982935
ABSTRACT
PURPOSE OF REVIEW Vasovagal syncope (VVS) is a common entity causing transient loss of consciousness and affecting quality of life. Guideline-recommended therapy involves conservative measures and pacing in selected patients. Cardioneuroablation (CNA) targeting the ganglionated plexi in the heart has been shown to reduce excessive vagal excitation, which plays a major role in the pathophysiology of VVS and functional bradycardia. RECENT FINDINGS:
The introduction of CNA has fueled research into its value for the treatment of VVS. Multiple observational studies and one randomized trial have demonstrated the safety and efficacy of CNA and the positive impact on quality of life. This review describes the rationale and CNA procedural techniques and outcomes. Patient selection and future directions have also been described. Cardioneuroablation is a promising treatment for patients with recurrent VVS and functional bradycardia. Further large-scale randomized studies are needed to further verify the safety and efficacy of this approach.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Bradicardia
/
Síncope Vasovagal
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article